ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Only Three Of 28 CCRU, CCSP Proposals Approved, But DRCCA Will Try Again, Board OKs New RFAs

May 13, 1983

GI Intergroup called a model for proposed scientific steering committees.

June 10, 2005

In Brief: House Fills Subcommittee Positions; Senate Schedules NCI Appropriations Hearing Feb. 18

February 13, 1981

DCCR Free Up $5 Million; New Policy Limits Core Support

November 5, 1976

New Patterns Of Care Study Okayed By DCT Board

June 13, 1986

GAO Suggests No Limit On Indirect Costs But Ceiling On Total Costs

September 7, 1979